Key Performance
More- Earnings Score: N/A
- Momentum Score: 84
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company developing molecular glue degrader medicines, announced it will participate in two investor conferences in May and June 2026, including fireside chats at the TD Cowen Oncology Innovation Summit and Jefferies Global Healthcare Conference. The company is advancing its pipeline of first-in-class MGD therapies with three programs currently in clinical development.
05/20/2026, 7:00 AM • GlobeNewswire
3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher
Despite a growing sentiment favoring industrial and dividend stocks in 2026, three high-risk stocks that surged over 100% in 2025 continue to show upside potential. FTAI Aviation benefits from GE Aerospace and Palantir partnerships, Kratos Defense gains from defense sector positioning, and Monte Rosa Therapeutics shows promise from positive clinical trial data. All three trade near or below analyst price targets with further upside expected.
02/06/2026, 12:16 PM • Investing
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company developing molecular glue degrader medicines, announced pricing of an underwritten public offering of 11.125 million shares at $24.00 per share and 1.375 million pre-funded warrants, expected to raise approximately $300 million gross proceeds. The offering is expected to close on January 12, 2026.
01/08/2026, 10:49 PM • GlobeNewswire
Monte Rosa Therapeutics presented preclinical data on MRT-8102, a molecular glue degrader targeting NEK7, which shows potential in treating cardiovascular and cardiometabolic diseases by modulating the NLRP3 inflammasome pathway.
11/08/2025, 11:30 AM • GlobeNewswire
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics announced CEO Markus Warmuth will participate in multiple healthcare investor conferences in November and December 2025, presenting the company's molecular glue degrader (MGD) research and developments.
11/03/2025, 7:00 AM • GlobeNewswire
Monte Rosa Therapeutics presented preclinical data on MRT-6160, a molecular glue degrader targeting VAV1, showing potential to treat multiple autoimmune and inflammatory diseases like systemic lupus erythematosus and rheumatoid arthritis in mouse models.
10/24/2025, 7:00 AM • GlobeNewswire
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
Monte Rosa Therapeutics announced a collaboration with Novartis to develop novel AI-powered degraders for immune-mediated diseases, receiving $120 million upfront and potential milestone payments up to $5.7 billion.
09/15/2025, 11:29 AM • Benzinga
Monte Rosa Therapeutics signed a collaboration agreement with Novartis to develop novel molecular glue degraders for immune-mediated diseases, receiving a $120 million upfront payment and potential milestone payments up to $5.7 billion.
09/15/2025, 7:00 AM • GlobeNewswire
Monte Rosa Therapeutics initiated a Phase 1 clinical study for MRT-8102, a molecular glue degrader targeting NEK7 for treating inflammatory diseases. The study includes single and multiple ascending dose cohorts in healthy volunteers, with initial results expected in H1 2026.
07/21/2025, 7:00 AM • GlobeNewswire
Monte Rosa Therapeutics published groundbreaking research in Science, using AI and machine learning to expand the potential target space for molecular glue degrader medicines, identifying over 100 protein target classes previously considered undruggable.
07/03/2025, 2:15 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.